Platelet rich plasma (PRP) is a blood plasma product that contains elevated level of platelets and growth factors (at least four to ten times) than normal blood concentration. PRP is also called as also called platelet enriched plasma and platelet gel. While mostly derived from patient’s own blood, platelet rich plasma is widely used in the treatment of diseases such as orthopedic diseases, neurological diseases, and other minor injuries that require outpatient surgeries. Rising incidence of diseases such as orthopedic diseases, sports injuries, cardiovascular diseases, obesity, and neurological diseases and introduction of various devices for PRP preparation are the key factors that are likely to drive market growth. In addition, growing awareness about PRP therapy and its advantages, and aging population more prone to injuries and surgeries are the other factors that boost market growth. However, high cost of the devices and therapy and threat of treatment failures are some of the factors restricting the market growth to some extent.

The autologous PRP segment dominated the PRP market in Europe in 2013. The dominance of this market segment was due to increasing demand for allogenic platelet rich plasma products. Thus, the allogenic segment is estimated to grow at the highest growth rate during the forecast period from 2014 to 2022. The growth of this market segment was majorly due to reduced wound healing time and high concentration of growth factors containing platelet rich plasma products.

Get PDF Brochure for more Professional and Technical industry insights: http://bit.ly/2dYDW9p

The rising prevalence of obesity and cardiovascular, neurological, and orthopedic disorders, the increasing cases of sports injuries, and the introduction of innovative and advanced devices for PRP preparation in Europe are bolstering the PRP market in this region. Additionally, the growing awareness among the European citizens regarding the PRP therapy and the benefits it offers is expected to support this market during the forecast period, notes the study.

In this report, the Europe PRP market has been studied on the basis of the region, PRP type, origin, and application. Regionally, the Europe market for PRP has been segmented into the U.K., Spain, France, Italy, Germany, and the Rest of Europe.

In 2013, the U.K. emerged as the leading domestic PRP market in Europe. The increase in orthopedic and reconstructive procedures, together with the rising number of bariatric surgeries, has boosted the U.K. PRP market significantly in the recent times. In addition to this, the increasing preference for PRP therapy in cases of sports injuries is likely to aid this market during the forecast period, states the research report.

Based on the type of PRP, the market has been classified into pure-platelet rich plasma (P-PRP), leukocyte-platelet rich fibrin (L-PRF), and leukocyte-platelet rich plasma (L-PRP). By origin, it has been segmented into allogenic, autologous, and homologous PRP. On the basis of application, the report has categorized the market into neurosurgery, cosmetic surgery, orthopedic surgery, general surgery, and various other surgeries such as cardiothoracic, oral, maxillofacial, urological, and periodontal surgeries.

The study also presents an assessment of the competitive landscape prevalent in the Europe PRP market. Based on in-depth research it has been stated that the market is highly fragmented due to the presence of a number of small as well as large international participants. Arthrex Inc. led the overall market in 2013. The company’s strong emphasis on marketing and distribution strategies in various European nations such as Italy, the U.K., the Netherlands, Spain, France, Germany, and Denmark has helped it significantly to achieve this position.

View exclusive Global strategic Business report : http://www.transparencymarketresearch.com/platelet-rich-plasma-market.html

A study on the Europe platelet rich plasma (PRP) market has been recently published by Transparency Market Research (TMR). According to this report, the PRP market in Europe was valued at US$42.1 mn in 2013. Analysts project this market to rise at a CAGR of 8.30% during the period from 2014 to 2022 and reach US$87.2 mn by the end of the forecast period.The research report is titled “Platelet Rich Plasma Market - Europe Industry Analysis, Size, Share, Growth, Trends & Forecast 2014 - 2022.”
Other key market participants mentioned in this study are Stryker Corp., Regen Lab S.A., Medira Ltd., Harvest Technologies Corp., Glofinn Oy, DePuy Synthes Inc., Biomet Inc., and AdiStem Ltd.

About Us
Transparency Market Research (TMR) is a global market intelligence company providing business information reports and services. The company’s exclusive blend of quantitative forecasting and trend analysis provides forward-looking insight for thousands of decision makers. TMR’s experienced team of analysts, researchers, and consultants use proprietary data sources and various tools and techniques to gather and analyze information.

Contact us:
Transparency Market Research
90 State Street,
Suite 700,
Albany
NY - 12207
United States
Tel: +1-518-618-1030
USA - Canada Toll Free 866-552-3453
Email: [email protected]
Website: http://www.transparencymarketresearch.com/